Essential Thrombocythemia

Overview

Essential thrombocythemia is a myeloproliferative neoplasm characterized by an increase in megakaryocytes and platelets

Essential thrombocythemia (ET) is a rare but serious myeloproliferative neoplasm (MPN) characterized by thrombocytosis with bone marrow megakaryocytic hyperplasia and a tendency to develop thrombotic and hemorrhagic complications.1-3

ET currently affects between 71,000 and 88,000 people in the United States

Between 71,000 and 88,000 people in the United States currently live with ET.4 ET is occasionally diagnosed in older children but most often occurs in adults.5 The typical pattern of ET onset is bimodal, with one peak occurring during young adulthood in women and the other peak occurring between the ages of 50 and 70 years in both men and women.6

Older Adults and Pregnant Women With ET May Face Serious Complications
ET can lead to serious complications, such as thrombosis, especially in patients3:
  • 60 years of age or older
  • with a history of major thrombosis
  • with elevated leukocyte counts at diagnosis
  • with hypertension
  • with diabetes
ET can also lead to complications in pregnancy. Pregnant women with ET have been reported to have live birth rates of 50% to 70% and spontaneous abortion rates of 25% to 50%.7
References

1. Cervantes F. Hematology. 2011;2011:215-221. 2. Tefferi A, Barbui T. Leukemia. 2013;27:1617-1620. 3. Wolanskyj AP, Schwager SM, McClure RF, et al. Mayo Clin Proc. 2006;81:159-166. 4. Incyte Corporation. Myelofibrosis epidemiology: a preliminary overview of data from available literature. July 2013. (Data on file.) 5. The Leukemia & Lymphoma Society. White Plains, NY; 2012. Number 12. 6. The Merck Manual for Healthcare Professionals. Available at:
http://www.merckmanuals.com/professional/hematology_and_oncology/myeloproliferative_disorders/essential_thrombocythemia.html. 2009. Updated February 2012. Accessed March 3, 2013. 7. Passamonti F, Randi ML, Rumi E, et al. Blood. 2007;110:485-489.